Prothena Plc Ownership
| PRTA Stock | USD 10.48 0.43 4.28% |
Shares in Circulation | First Issued 2012-03-31 | Previous Quarter 53.8 M | Current Value 53.8 M | Avarage Shares Outstanding 38.3 M | Quarterly Volatility 12.2 M |
Prothena Stock Ownership Analysis
About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.83. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Prothena plc has Price/Earnings To Growth (PEG) ratio of 0.8. The entity recorded a loss per share of 5.2. The firm had not issued any dividends in recent years. Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company was founded in 2012 and is based in Dublin, Ireland. Prothena Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people. To find out more about Prothena plc contact the company at 353 1 236 2500 or learn more at https://www.prothena.com.Besides selling stocks to institutional investors, Prothena Plc also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Prothena Plc's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Prothena Plc's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Prothena Plc Quarterly Liabilities And Stockholders Equity |
|
Prothena Plc Insider Trades History
About 19.0% of Prothena plc are currently held by insiders. Unlike Prothena Plc's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Prothena Plc's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Prothena Plc's insider trades
Prothena Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Prothena Plc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Prothena plc backward and forwards among themselves. Prothena Plc's institutional investor refers to the entity that pools money to purchase Prothena Plc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2025-06-30 | 933.4 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 693.2 K | Balyasny Asset Management Llc | 2025-06-30 | 575.8 K | Trexquant Investment Lp | 2025-06-30 | 552.8 K | Goldman Sachs Group Inc | 2025-06-30 | 528.3 K | Cubist Systematic Strategies, Llc | 2025-06-30 | 501.8 K | Rock Springs Capital Management Lp | 2025-06-30 | 492.6 K | Granahan Investment Management Inc.. | 2025-06-30 | 461.1 K | Birchview Capital, Lp | 2025-06-30 | 451 K | Fmr Inc | 2025-06-30 | 7.9 M | Blackrock Inc | 2025-06-30 | 3.9 M |
Prothena plc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prothena Plc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prothena Plc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Prothena Plc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prothena Plc Outstanding Bonds
Prothena Plc issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Prothena plc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Prothena bonds can be classified according to their maturity, which is the date when Prothena plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Prothena Plc Corporate Filings
8K | 19th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of November 2025 Other Reports | ViewVerify | |
| 7th of October 2025 Other Reports | ViewVerify | |
| 25th of September 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prothena plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Prothena Plc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prothena Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prothena Plc Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prothena plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.20) | Revenue Per Share | Quarterly Revenue Growth 1.49 | Return On Assets | Return On Equity |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.